Tue, May 7, 2013
Mon, May 6, 2013
Sun, May 5, 2013
Fri, May 3, 2013
Thu, May 2, 2013
Wed, May 1, 2013
Tue, April 30, 2013
Mon, April 29, 2013
Sun, April 28, 2013
Fri, April 26, 2013
Thu, April 25, 2013
Wed, April 24, 2013
Tue, April 23, 2013
Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013

Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call


//health-fitness.news-articles.net/content/2013/ .. -financial-results-and-host-conference-call.html
Published in Health and Fitness on by Market Wire   Print publication without navigation



April 26, 2013 09:00 ET

Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call

MENLO PARK, CA--(Marketwired - Apr 26, 2013) - Corcept Therapeutics Incorporated (NASDAQ: [ CORT ]) today announced it will report first quarter 2013 financial results on May 2, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-888-771-4371 from the United States or 1-847-585-4405 internationally approximately 10 minutes before the start of the call. The passcode is 34774024.

A replay will be available through May 16, 2013 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The passcode is 34774024.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders. In April 2012, Corcept began offering its first product, Korlym® (mifepristone) 300 mg Tablets, a first-generation GR-II antagonist, as a once-daily oral treatment of hyperglycemia secondary to endogenous Cushing's syndrome in adult patients who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

The company has a phase 3 trial underway for mifepristone for treatment of the psychotic features of psychotic depression and a portfolio of selective GR-II antagonists that block the effects of cortisol but not progesterone. It owns extensive intellectual property covering the use of GR-II antagonists, including mifepristone, in the treatment of a wide variety of metabolic and psychiatric disorders. It also holds composition of matter patents for its selective GR-II antagonists.



Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear